Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Thrombosis 1Squamous Cell Carcinoma of Head and Neck 1Sexuality 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Radiation Injuries 1Protein Metabolism 1Pain 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Malnutrition 1Hemorrhage 1Glioblastoma 1Erectile Dysfunction 1Disease 1Diabetes Insipidus 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × Arginine × Clear all
NCT02844387 2016-07-28

Supplementation of L-arginine in Patients With Non-resectable Brain Metastases

Instituto de Oncología Ángel H. Roffo

Phase 1/2 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡